The leadership team for the soon-to-be-separated Medtronic Diabetes business — MiniMed — is beginning to take shape.
Our sister site, Drug Delivery Business News, reports today that the company appointed Chad Spooner as CFO of MiniMed in advance of its intended separation.
Effective July 14, Spooner takes responsibility for overseeing the finance function for Medtronic Diabetes/MiniMed. His role includes supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as the unit prepares to become independent.
Spooner offers more than 25 years of experience in financial leadership across the healthcare, consumer and industrial sectors. Most recently, he served as CFO of BIC, a publicly traded global consumer goods leader.
Medtech giant Medtronic announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes, called MiniMed.
Get the full story at our sister site, Drug Delivery Business News.
